Previous 10 | Next 10 |
Acer Therapeutics Inc. (NASDAQ: ACER ) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts, focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening orphan or ultra-orphan diseases with signifi...
RADNOR, Pa., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP reminds Acer Therapeutics, Inc. (Nasdaq: ACER) (“Acer”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Southern Distri...
NEWTON, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced th...
RADNOR, PA / ACCESSWIRE / August 23, 2019 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds Acer Therapeutics, Inc. (Nasdaq:ACER) (“Acer”) investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or otherwise acquir...
Acer Therapeutics (NASDAQ: ACER ): Q2 GAAP EPS of -$1.09 misses by $0.31 . More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEWTON, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported fin...
NEWTON, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced th...
NEWTON, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced it...
RADNOR, Pa., July 24, 2019 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds Acer Therapeutics, Inc. (Nasdaq: ACER) (“Acer”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the...
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Acer Therapeutics Inc. (NASDAQ: ACER) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between September 25, 2017 and June 24, 2019. Acer Therapeutics is a pharmaceutical...
News, Short Squeeze, Breakout and More Instantly...
Acer Therapeutics Inc. Company Name:
ACER Stock Symbol:
NASDAQ Market:
Acer Therapeutics Inc. Website:
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Acer Therapeutics Inc. (ACER) is expected to report $-0.13 for Q3 2023